Interventional Left Ventricular Assist System for PCI in CHIP Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

286 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-06

Study Completion Date

2027-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Mechanical circulatory support (MCS) is a life-sustaining therapy first introduced in the 1950s. After six decades of development, it now serves as a critical bridge therapy for patients with acute cardiac events and end-stage heart failure. Percutaneous mechanical circulatory support (pMCS), a key MCS modality, has advanced rapidly in recent years.

In China, pMCS adoption has accelerated significantly, evidenced by year-over-year growth in both specialized centers and clinical cases, alongside continuous technological refinement.

Common pMCS devices include: Intra-Aortic Balloon Pump (IABP), Axial flow pump systems (e.g., Impella®), Extracorporeal Membrane Oxygenation (ECMO). However, no randomized study has compared Impella with VA-ECMO in CHIP patients.

The aim of the study is to evaluate the effectiveness and safety of interventional left ventricular assist system (VADLINK) compared to the VA-ECMO in providing circulatory support for complicated and high-risk patient with indications for PCI.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial of Ventiflow LP Supporting High-risk Percutaneous Coronary Intervention(PCI)

NCT06754839

Coronary Artery Disease Heart Failure High-risk PCI

NOT_YET_RECRUITING NA

Phimume® Percutaneous Left Ventricular Assist System Study

NCT06639321

Coronary Artery Disease

NOT_YET_RECRUITING NA

Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or Severe Mitral Regurgitation in China

NCT05610566

Mitral Regurgitation

RECRUITING NA

Temporary MCS With the iVAC 2L Transaortic Device in High-risk PCI

NCT07149714

Ischemic Cardiovascular Disease Multivessel Coronary Artery Disease Coronary Artery Disease +4 more

RECRUITING NA

Phase II Clinical Trial of Percutaneous Ventricular Restoration Using Heartech® Device Preventing Heart Failure Post Myocardial Infarction (The Partical Study)

NCT04039256

Efficacy, Safty, Device

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

High-Risk Percutaneous Coronary Intervention (High-risk PCI) Left Ventricular Assist Devices

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VADLINK

The VADLINK percutaneous left ventricular assist system will offer intraoperative hemodynamic support during high-risk PCI procedures.

Group Type EXPERIMENTAL

Implantation of the VADLINK Percutaneous Left Ventricular Assist Device

Intervention Type DEVICE

To implant VADLINK percutaneous left ventricular assist device during percutaneous coronary intervention (PCI).

V-A ECMO

The VA-ECMO offers intraoperative hemodynamic support during high-risk PCI procedures.

Group Type ACTIVE_COMPARATOR

VA-ECMO

Intervention Type DEVICE

Received venous arterial extracorporeal membrane oxygenation (VA-ECMO) during PCI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantation of the VADLINK Percutaneous Left Ventricular Assist Device

To implant VADLINK percutaneous left ventricular assist device during percutaneous coronary intervention (PCI).

Intervention Type DEVICE

VA-ECMO

Received venous arterial extracorporeal membrane oxygenation (VA-ECMO) during PCI.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1\. Aged 18-90 2. The investigator assesses that the subject requires coronary revascularization, but CABG (Coronary Artery Bypass Grafting) is considered high-risk or the subject refuses CABG. The investigator believes the subject may benefit from PCI (Percutaneous Coronary Intervention).

3\. Left ventricular ejection fraction (LVEF) ≤ 35%. 4. Coronary angiography (CAG) or coronary computed tomography angiography (CTA) shows any of the following conditions:

1. Unprotected left main (LM) coronary artery disease (coronary stenosis ≥ 50%).
2. A last remaining patent coronary artery (the anterior descending artery (LAD) and/or its branches, the circumflex artery (LCX) and/or its branches, and the right coronary artery (RCA) and/or its branches).
3. Saphenous vein graft (SVG) vascular lesions.
4. Severely calcification, tortuosity.
5. Multivessel disease (two or more) combined with chronic total occlusion (CTO).
6. Three-vessel disease. Three-vessel disease is defined as significant stenosis (≥ 70%) in at least one segment of all three major epicardial coronary artery territories: the left anterior descending artery (LAD) and/or its branches, the left circumflex artery (LCX) and/or its branches, and the right coronary artery (RCA) and/or its branches. In a left-dominant coronary system, lesions in the proximal segments of the LAD and LCX are also considered three-vessel disease.

5\. Patients who are able to give informed consent and complete the follow-up.

Exclusion Criteria

1. Cardiogenic shock (CS) within 7 days (Cardiogenic shock: Sustained SBP \<90 mmHg for ≥30 min or requiring supportive measures to maintain SBP \>90 mmHg and end-organ hypoperfusion (urine output \<30 ml/h or cool extremities).
2. STEMI or CK-MB did not return to the normal range within 24 hours.
3. Cardiac arrest with cardiopulmonary resuscitation within 24 hours.
4. Left ventricular mural thrombus.
5. After aortic valve replacement surgery (mechanical, bioprosthetic).
6. Having used or using ECMO or pVAD (percutaneous ventricular assist device) within 7 days.
7. Moderate to severe aortic stenosis, moderate to severe aortic valve insufficiency.
8. Atrial septal or ventricular septal defects (including post-infarction VSD), or post-myocardial infarction Free-Wall Rupture, or papillary muscle rupture.
9. Severe right heart failure or severe tricuspid valve insufficiency.
10. Disease or abnormality of the aorta that interferes with the procedure, including Marfan syndrome, coarctation of aortic, aortic aneurysm, severe tortuosity or calcification of the aorta.
11. Severe peripheral arterial stenosis or occlusive lesions.
12. Uncorrectable moderate or severe anemia prior to the procedure (hemoglobin \<90 g/L). Abnormal coagulation function (routine blood test indicates platelet count less than 75×109/L, INR ≥2.0, or fibrinogen ≤1.5 g/L).
13. Known contraindications to heparin, contrast agents, or study-required medications (e.g., aspirin, clopidogrel); history of Heparin-induced thrombocytopenia.
14. Active hemorrhage within 1 month.
15. History of stroke or TIA or permanent neurologic deficits within one month prior to the procedure.
16. Renal dysfunction: subject on dialysis or serum creatinine ≥4 mg/dL (353.6 µmol/L) within 7 days.
17. Liver dysfunction: liver AST, ALT and bilirubin \>3 times the upper limit of normal within 7 days.
18. Presence or suspected presence of infective endocarditis or systemic infection.
19. Women who are pregnant, breastfeeding, or planning pregnancy during the trial.
20. Participation in another drug or medical device clinical trial.
21. Other conditions deemed by the investigator as unsuitable for participation in this trial.

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.